Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's revenue declined by 25% YoY, and net losses increased by 10% due to higher R&D expenses. Additionally, there are significant risks related to regulatory approvals, NASDAQ compliance, and financial stability. No new partnerships or positive strategic updates were announced. The lack of positive catalysts and increased uncertainties suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Key Financial Performance
Revenue The company reported revenue of $2.5 million for Q1 2026, which represents a 25% decrease year-over-year. The decline was attributed to lower licensing fees compared to the same period last year.
Research and Development Expenses R&D expenses were $8.2 million, up 15% year-over-year. The increase was due to higher costs associated with advancing clinical trials for the company's oral vaccine candidates.
Net Loss Net loss for the quarter was $12.3 million, an increase of 10% year-over-year. This was primarily driven by higher R&D expenses and lower revenue.
Cash and Cash Equivalents The company ended the quarter with $95 million in cash and cash equivalents, down from $110 million at the end of Q1 2025. The decrease was due to ongoing operational expenses and investments in clinical trials.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: Uncertainty in obtaining anticipated regulatory approvals for products, which could delay or hinder product launches and revenue generation.
NASDAQ Listing Compliance: Risk of failing to regain compliance with NASDAQ listing standards, potentially impacting the company's ability to raise capital and maintain investor confidence.
Clinical Development Process: Inherent uncertainties in the clinical development process, which could lead to delays or failures in product development.
Financial Stability: Dependence on raising capital to sustain operations, with potential challenges if capital is not secured.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Financial Guidance: Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations, any partnerships with third parties, timing of any anticipated regulatory approvals or that any such approvals will be obtained, the company's future cash runway, ability to regain compliance with NASDAQ listing standards or raised capital of such listing is regained, and its product development and regulatory process, including statements about its ongoing or planned clinical trials.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounting Officer
Berg Senior
CEO Director
CFO Principal
Chat Conference
Conference Instructions
Counsel PM
Cummings Chief
Director Cummings
EDT Finn
Edward Berg
Finn Partners
Fireside Chat
Grasman CFO
Greetings Stockholder
Inc Greetings
Jeroen Grasman
Lo President
Officer Edward
Officer Jeroen
PM EDT
Partners Inc
Partners result
President CEO
Sean Tucker
Senior VP
Stockholder Fireside
Tucker Senior
webcast Finn
VXRT Transcript
Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript
Unknown5-8
The company's revenue declined by 25% YoY, and net losses increased by 10% due to higher R&D expenses. Additionally, there are significant risks related to regulatory approvals, NASDAQ compliance, and financial stability. No new partnerships or positive strategic updates were announced. The lack of positive catalysts and increased uncertainties suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Vaxart, Inc. (VXRT) Q4 2025 Earnings Call Transcript
Unknown3-12
The earnings call highlights a significant revenue increase and a strong cash position extending into 2027, which is positive. However, the delay in COVID-19 trial data, regulatory uncertainties, and heavy reliance on partnerships introduce risk. The Dynavax partnership is a potential positive catalyst, but the lack of clear guidance and delayed data releases temper expectations. Thus, the overall sentiment is neutral, with no strong catalysts for significant stock movement in the short term.
Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call highlights a significant revenue increase and extended cash runway, which are positive. However, the dependency on partnerships for advancing the norovirus program and the BARDA stop work order pose risks. The Q&A session revealed uncertainty about independent trial initiation for the norovirus program, reflecting potential challenges. These mixed signals suggest a neutral sentiment, with positive financials balanced by strategic uncertainties.
Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call presented a mixed outlook. Positive aspects include revenue growth, a strong cash runway, and promising vaccine developments. However, workforce reductions, dependency on external funding for trials, and uncertainties in partnerships and trial progress are concerning. The Q&A highlighted management's lack of clarity on key issues, such as the COVID-19 trial's stop work order, which raises uncertainty. Despite potential catalysts like the avian flu vaccine, uncertainties and financial challenges balance out the positives, leading to a neutral sentiment.
VXRT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
